Navigation Links
Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that scientists from the company will present results of two preclinical studies with sapacitabine and seliciclib, the company's most advanced drug candidates in clinical development. The results will be reported in two poster presentations during the upcoming Annual Meeting of the American Association for Cancer Research (AACR) taking place at the Los Angeles Convention Center between April 14-18, 2007. Sapacitabine is an orally-available, novel nucleoside analog in Phase I clinical trials in patients with solid and hematological cancers. Seliciclib is the most advanced orally-available, cyclin dependent kinase (CDK) inhibitor in Phase II clinical development in patients with non-small cell lung cancer. Sapacitabine and seliciclib are the lead drug candidates in Cyclacel's pipeline of small molecule cell cycle inhibitors. -0-
The schedule of Cyclacel's presentations is as follows:


       Date          Time (PDT)          Title            Poster

                                                       Number/Session


Monday, April 16    1 PM - 5 PM   Identification of   # 3183

                                   biomarkers to aid  Poster Session

                                   clinical            24, South Hall

                                   development of

                                   sapacitabine

                                   (CYC682), a novel

                                   nucleoside analog


Tuesday, April 17   8 AM - 12 PM  Synergistic         # 4003

                                   combinations       Poster Session

                                   between the oral    31,

                                   CDK inhibitor,     South Hall

                                   seliciclib, and

                                   EGFR inhibitors in

                                   NSCLC


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... 15, 2014A prospective study that compared patient-reported outcomes ... bone metastases demonstrates that single fraction radiation therapy ... radiation therapy (MFRT) when pain, function and quality ... today at the American Society for Radiation Oncology,s ... that improvements in patients, pain, function and degree ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral ... political organization fighting to legalize medical marijuana in Florida. ... After Party recently commissioned a shot-for-shot parody video of ... the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re ... musical parody faithfully recreates the carnival scene made famous ...
(Date:9/16/2014)... September 16, 2014 Florida Hospital announced ... Lightning to extend its partnership and become the Presenting ... as the team’s official health and wellness partner. As ... Hospital will receive a logo and name inclusion on ... two seasons. Florida Hospital has been a sponsorship partner ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Brunswick are facing one of the worst gastroenteritis epidemics ... gear, with patients coming// in droves for relief. The ... continue for a few days but seldom endangers life. ... greater Montreal area have reported the viral outbreak. Dr. ...
... nutrient folate through both diet and supplements may have ... a report in the January issue of Archives of ... year 2047, the prevalence of Alzheimer’s disease is expected ... Delaying the onset of this neurodegenerative disease would significantly ...
... fight malaria in Africa has received its first-ever challenge ... pledge// to match dollar for dollar up to $3 ... a disease that kills more than 1 million people ... ‘Nothing But Nets’ campaign, a partnership between the UN ...
... Welcome to another cold season. If you’re like most adults, ... especially preschoolers, have it worse//, getting as many as eight ... Mayo Clinic Women’s HealthSource offers insights on how you can ... ,It’s a virus, not the temperature, that causes colds. ...
... to improve the treatment given to people bitten by snakes or ... ,Africa, Latin America and Asia are the most affected ... it comes to snake bite, the actual number of death is ... intervention. ,According to a WHO release, rabies figures tenth ...
... disease. Yet recent studies have shown that the chance of ... and exercise//, the chances of surviving it, also depend on ... putting around 50,000 pounds behind a study to be carried ... will involve cancer survivors aged above fifty and with a ...
Cached Medicine News:Health News:Higher Folate Levels Linked to Reduced Risk for Alzheimer’s Diseas 2Health News:Yes, Chicken Soup Can Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: